YNYukio Nihei

Yukio Nihei

*This is an algorithmically generated author record based on publicly available information.

Yukio Nihei has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Akira Okano

    Pharmaceutical Research Laboratories, Ajinomoto Co., Inc., 1–1 Suzuki‐cho, Kawasaki‐ku, Kawasaki 210–8681

    2 shared publications
  • Katsuyoshi Hori

    Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University, 4–1 Seiryo‐cho, Aoba‐ku, Sendai 980–0872

    2 shared publications
  • Sachiko Saito

    Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University, 4–1 Seiryo‐cho, Aoba‐ku, Sendai 980–0872

    2 shared publications
  • Takashi Tsuruo

    Laboratory of Biomedical Research, Institute of Molecular and Cellular Biosciences, University of Tokyo, 1‐1‐1 Yayoi, Bunkyo‐ku, Tokyo 113–0032

    2 shared publications
  • Yasufumi Sato

    Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University, 4–1 Seiryo‐cho, Aoba‐ku, Sendai 980–0872

    2 shared publications
  • Yukio Akiyama

    Pharmaceutical Research Laboratories, Ajinomoto Co., Inc., 1–1 Suzuki‐cho, Kawasaki‐ku, Kawasaki 210–8681

    2 shared publications

Latest Publications

    • 1 December 1999
      • Vol. 14  (6) , 539-48

    Synthesis and antitumor activities of amino acid prodrugs of amino-combretastatins.

    by K Ohsumi, T Hatanaka, R Nakagawa, Y Fukuda, Y Morinaga, Y Suga, Y Nihei, K Ohishi, Y Akiyama, T Tsuji

    The synthesis and antitumor activity of water-soluble amino acid prodrugs of amino-combretastatins were reported. Among the synthesized compounds, 7e (CS-39-L-Ser HCI, AC-7700) showed enhanced antitumor activity and decreased toxicity in a Colon 26 murine adenocarcinoma model. Compound 7e showed improved solubility and was easily formulated for in vivo administration. Compound 7e was cleaved to generate the parent compound, CS-39, in the whole blood of mice as well as man, possibly by the action of amino peptidase on the erythrocyte membrane.


  • Evaluation of Antivascular and Antimitotic Effects of Tubulin Binding Agents in Solid Tumor Therapy

    by Yukio Nihei, Manabu Suzuki, Akira Okano, Takashi Tsuji, Yukio Akiyama, Takashi Tsuruo, Sachiko Saito, Katsuyoshi Hori, Yasufumi Sato

    Tubulin binding agents (TBAs) reduce tumor perfusion and inhibit mitosis of tumor cells in solid tumors, but it is not clear which effects contribute to the suppression of solid tumor growth. We evaluated the antivascular and antimitotic effects of several TBAs, combretastatin A‐4 (CS A‐4) phosphate, AC‐7700, a novel CS A‐4 derivative, colchicine, E7010, and vinblastine, on subcutaneous (s.c.) murine colon26 adenocarcinoma (c26). Tolerable doses of vinblastine and E7010 strongly inhibited tumor growth and induced mitotic arrest of tumor cells without affecting tumor perfusion. Colchicine had no effect on tumor growth and perfusion. When the injected dose was increased to the lethal range, however, these drugs markedly reduced tumor perfusion and caused necrosis of tumor tissue. Within the tolerable dose range, AC‐7700 both strongly suppressed tumor growth and reduced tumor perfusion, and CS A‐4 phosphate also exhibited a moderate antivascular effect. To evaluate the contribution of antivascular activity of TBAs to tumor growth suppression, excluding their direct cytotoxic effect on tumor cells, we established c26/acr, which is resistant to TBAs in vitro. Although E7010 showed a reduced suppressive effect on s.c. c26/acr tumor growth as compared with its effect on wild‐type c26, AC‐7700 remained potent against both cell lines. These results indicate that TBAs exert antivascular and antimitotic effects on solid tumors with marked differently effective dose ranges from agent to agent, and that the antivascular effect of TBAs inhibits solid tumor growth independently of the direct cytotoxic effect on tumor cells.


  • A Novel Combretastatin A‐4 Derivative, AC‐7700, Shows Marked Antitumor Activity against Advanced Solid Tumors and Orthotopically Transplanted Tumors

    by Yukio Nihei, Yasuyo Suga, Yoshihiro Morinaga, Kazuo Ohishi, Akira Okano, Koji Ohsumi, Toshihiro Hatanaka, Ryusuke Nakagawa, Yukio Akiyama, Sachiko Saito, et al.

    AC‐7700, a novel combretastatin A‐4 derivative, suppresses the growth of solid tumors by inhibiting tumor perfusion. We evaluated the antitumor activity of AC‐7700 on solid tumors in two experimental models, an advanced tumor model (murine colon 26 (c26) adenocarcinoma, colon 38 (c38) adenocarcinoma, MethA fibrosarcoma, Sarcoma 180 (S180), Lewis lung carcinoma (3LL), human LS180 adenocarcinoma) and an orthotopically transplanted tumor model (c26), compared with that of cisplatin (CDDP). The maximum tolerable dose (MTD) of CDDP suppressed early‐stage c26 and c38 tumor growth when treatment was started after the tumor volume (TV) reached 0.2–0.5 cm3, but it showed reduced activity against the same tumors at an advanced growth stage when TV exceeded 2 cm3. At its MTD, AC‐7700 was active against all tumors tested except 3LL in both early and advanced growth stages, reducing the tumor mass and having a curative effect in advanced c38 tumors. AC‐7700 was also effective on orthotopically transplanted c26 tumors, showing a comparable activity to that on subcutaneous tumors. Unlike flavon acetic acid, which damages tumor vasculature by inducing endogenous tumor necrosis factor‐α production, AC‐7700 potently suppressed the growth of advanced c26 tumors in athymic as well as euthymic mice. These results suggest that AC‐7700 is a novel antivascular agent that may have potent activity against advanced‐stage cancer in the clinical setting.